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Burkitt lymphoma (BL) is classified into
3 clinical subsets: endemic, sporadic, and
immunodeficiency-associated BL. So far,
possible differences in their gene expres-
sion profiles (GEPs) have not been inves-
tigated. We studied GEPs of BL subtypes,
other B-cell lymphomas, and B lympho-
cytes; first, we found that BL is a unique
molecular entity, distinct from other
B-cell malignancies. Indeed, by unsuper-
vised analysis all BLs clearly clustered
apart of other lymphomas. Second, we
found that BL subtypes presented slight
differences in GEPs. Particularly, they
differed for genes involved in cell cycle
control, B-cell receptor signaling, and
tumor necrosis factor/nuclear factor B
pathways. Notably, by reverse engineer-
ing, we found that endemic and sporadic
BLs diverged for genes dependent on
RBL2 activity. Furthermore, we found that
all BLs were intimately related to germi-
nal center cells, differing from them for
molecules involved in cell proliferation,
immune response, and signal transduc-
tion. Finally, to validate GEP, we applied
immunohistochemistry to a large panel of
cases and showed that RBL2 can cooper-
ate with MYC in inducing a neoplastic
phenotype in vitro and in vivo. In conclu-
sion, our study provided substantial in-
sights on the pathobiology of BLs, by
offering novel evidences that may be rel-
evant for its classification and possibly
future treatment. (Blood. 2011;117(13):
3596-3608)
Introduction
Burkitt lymphoma (BL) is listed in the World Health Organization
(WHO) classification of lymphoid tumors as a single genetic and
morphologic entity with variable clinical presentation.1 In particu-
lar, the WHO classification recognizes 3 clinical subsets of BL:
endemic (eBL), sporadic (sBL), and immunodeficiency-associated
(ID-BL). Each affects different populations and can present with
different features.
The endemic form is overall the commonest type, being the
most frequent childhood cancer in equatorial Africa.1-4 eBL is
almost invariably associated with Epstein-Barr virus (EBV) infec-
tion, although local environmental toxics (ie, Euphorbia tirucalli)
and coinfection with arbovirus or, specially, malaria also appear to
be important for its pathogenesis.5-7
sBL is the most commonly recorded form in the United States
and Europe. As opposed to eBL, only  20% of cases are
associated with EBV.8
Immunodeficiency-associated BL occurs more commonly in
patients infected with HIV (HIV-BL) and rarely in patients who
have undergone organ transplantation.9 Intriguingly, because
HIV-BL can occur in patients with relatively high CD4 counts,
immunnosuppression per se is not sufficient to explain the rela-
tively high prevalence of BL in this setting.10,11 On clinical ground,
the link between EBV and HIV-BL is less clear than for eBL.1,12,13
On the basis of morphology, phenotype, and genetics, BL is
currently regarded as a germinal center (GC)–derived neoplasm.1
Nevertheless, according to the somatic hypermutation (SH) pat-
terns and the expression of specific EBV-related molecules, in the
WHO classification a different origin for the endemic and sporadic
forms has been suggested.1,14,15
At genetics, BL molecular hallmark is the ectopic expression of
the MYC oncogene, because of reciprocal chromosomal transloca-
tions, juxtaposing MYC to the immunoglobulin heavy chain
(IGH@) locus [(t(8;14)(q24;q32)] or the  or  light chain loci
[(t(2;8)(p12;q24) and t(8;22)(q24;q11), respectively]. Interestingly,
differences in the break point on chromosome 14 for the transloca-
tion of MYC to the IGH@ locus, as well as in the mutation pattern
of the 5-region of MYC, have been recorded between eBL and
sBL.16 In addition, although all BLs have similar phenotype and
MYC translocation, it has been argued that the 3 subtypes may have
different pathogenetic mechanisms. In particular, because of the
peculiar association patterns, a role for EBV has been proposed.15
However, there is still no satisfactory explanation of whether and
how EBV participates in the pathogenesis of BLs, and it is probable
that different (or multiple) environmental exposures may converge
in a common pathogenetic mechanism.
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Recently, 2 independent studies documented that sBL has a
unique gene expression profile (GEP), distinct from those of other
B non-Hodgkin lymphomas (B-NHLs) and, especially, that of
diffuse large B-cell lymphoma (DLBCL).17,18 However, no GEP
study has included all BL subtypes so far.
In this study, we performed a gene expression analysis of eBL,
sBL, and HIV-BL cases as well as of a large panel of B cell–derived
malignancies and normal B-cell populations to (1) assess whether
BL subtypes present with differences in their GEPs, (2) investigate the
relationship of the different BL subtypes with the nonneoplastic cellular
counterparts, and (3) identify genes and programs specifically deregu-
lated in BLs and possibly contributing to the malignant phenotype.
Methods
Case selection
One hundred fifty-two B cell–derived malignancies and 20 samples of
normal B-cell subpopulations were studied by GEP analysis. In particular,
we studied 40 BL samples (13 eBLs, 21 sBLs 6 HIV-BLs), together with
Figure 1. BL is a unique entity distinct from other
B-cell malignancies. The unsupervised hierarchical
clustering, based on the expression of the 9848 most
informative genes, clearly separated the different dis-
eases. In particular, eBL, sBL, and HIV-BL were grouped
within a unique cluster. The dendrogram was generated
with the use of a hierarchical clustering algorithm that
was based on the average-linkage method. In the
matrix, each column represents a sample and each row
represents a gene. The color scale bar shows the
relative gene expression changes normalized by the
standard deviation (0 is the mean expression level of a
given gene).
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40 follicular lymphomas (FLs), 10 chronic lymphocytic leukemia (CLL)
samples, 10 GC B-type DLBCL, 10 ABC-type DLBCL, 5 primary
mediastinal B-cell lymphomas, 13 HIV-related DLBCL, and 34 marginal
zone lymphomas (MZLs). In addition, we analyzed 20 samples of normal
B-cell subpopulations, including GC (n  10), naive (n  5), and memory
(n  5) cells. Details on such cases are provided in supplemental File
1 (available on the Blood Web site; see the Supplemental Materials link at
the top of the online article).
All diagnoses were reviewed by  2 expert hematopathologists (S.A.P.
and L.L.) and were formulated according to the WHO classification.1 All of
the samples were obtained at the time of diagnosis, before treatment
administration. The histopathologic characteristics of the 16 BL cases for
which GEPs were generated are summarized in supplemental Table 1.
Briefly, all cases were t(8;14)-positive, and the immunophenotype was
consistent with the diagnosis (CD10, CD20, BCL6, Ki67  98%,
BCL2). All cases but 2 HIV-BLs and the sBL were EBV.
In addition, 356 cases were studied by immunohistochemistry for validation
purposes (details are presented in Table 3 and supplemental File 1).
The study was approved by each institutional ethical committee, and
written permission and informed consent have been obtained before sample
collection in accordance with the Declaration of Helsinki. In particular, this
study is a part of an integrated project approved by the Italian government,
involving the pathology departments of the University of Siena, the
University of Bologna in Italy, and the Lacor Hospital (Gulu) and the
Makerere University (Kampala) in Uganda, as well as other European
institutions.
Gene expression profiling
Total RNA was extracted with the use of the TRIzol reagent (Invitrogen and
Life Technologies), purified with the use of the RNeasy Kit (QIAGEN), and
processed according to the Affymetrix Expression Analysis Technical
Manual. Fragmented cRNA (15 	g) was hybridized to HG-U133 2.0 Plus
microarrays (Affymetrix). The gene expression values were determined by
MAS 5 algorithm in Expression Console (Affymetrix), and normalization
was performed by scaling to a target intensity of 500. Normalization quality
control was performed by box-plot and MA plot consistency.
Gene expression analysis was carried out as previously reported.19,20
For details, see supplemental File 1.
Gene expression studies were conducted according to Minimum
Information About a Microarray Experiment (MIAMI) guidelines. Raw
gene expression data are available at http://www.ncbi.nlm.nih.gov/projects/
geo/ under accession number GSE26673.
Cell transfection and gene silencing
To evaluate the possible pathogenetic relevance of additional genomic
events rather than MYC translocation in eBL, we generated an experimental
model that was based on GEP results, by engineering a normal
B-lymphoblastoid cell line (LCL; a kind gift of Prof A. Lanzavecchia, IRB
Bellinzona, Switzerland). First, to mimic MYC ectopic expression, we
induced MYC expression by transfection (pcDNA3-MYC), followed by
antibiotic selection, as previously described.21 Selected clones, which
showed high MYC expression, were then used for further genetic engineer-
ing. Second, we induced RBL2/p130 gene silencing to reproduce the
functional consequences of mutations occurring in primary eBL cases.22,23
Such abnormality was chosen as an example of additional events as
(1) consistently recurrent in eBL,22 (2) recently characterized by our group
as functionally relevant ex vivo,23 (3) possible object of further investiga-
tion by a novel bioinformatic tool (Algorithm for the Reconstruction of
Accurate Cellular Networks; ARACNe) involving a transcription factor
(see “The proliferation signature of endemic BL relies on either MYC
expression and other factors”), and (4) the RBL2 network, as inferred by
ARACNe, being enriched in eBL signature (see “The proliferation signa-
ture of endemic BL relies on either MYC expression and other factors”).
For details, see supplemental File 1.
Soft agar and invasion capability assays
Soft agar assays were performed as described with minor modifications,24
and invasion capability was then tested by CytoSelect 24-well Cell Invasion
Assay, Basement Membrane on Colorimetric format (Cell Biolabs), accord-
ing to the manufacturer’s instruction. All the experiments were performed
in triplicate and repeated 3 times. Further details are provided in the
supplemental File 1.
Xenografted mouse model for in vivo validation
Animal care and humane use and treatment of mice were in strict
compliance with (1) institutional guidelines, (2) the Guide for the Care and
Use of Laboratory Animals (National Academy of Sciences, 1996), and
(3) the Association for Assessment and Accreditation of Laboratory Animal
Care International. In addition, specific consent was obtained from the Central
Ethical Committee of the Italian government for all animal experiments.
Briefly, cells carrying both genetic alterations, which resulted to have
transforming potential in vitro, were then tested for their capability of
generating tumors in vivo. As a control, cells with only either MYC
overexpressed or RBL2 silencing were used, as well as cells transfected
with the empty vector and untransfected cells. Tumors were generated by
the intraperitoneal injection of 10 
 106 cells into nude mice (Harlan).
Tumor formation in mice was carefully monitored, and after 4 weeks mice
were killed for pathologic assessments.
Statistical analyses
Statistical analyses were carried out with the StatView 5.0 software package
(SAS Institute Inc). Differences in colony formation, Matrigel invasion, and
tumor formation in mice were evaluated by 2-sided Student t test,
Mann-Whitney U test, Fisher exact test, or 2 test when appropriate. The
limit of significance for all analyses was defined as P  .05.
Results
BL has a relatively homogeneous molecular phenotype distinct
from other B-cell malignancies
BL subtypes, at present, are defined only on the basis of clinical/
epidemiologic features. To assess whether BLs have a homoge-
neous GEP, we tested by unsupervised analysis all BL subtypes
(endemic, sporadic, and HIV) and a large panel of B cell–derived
malignancies, including FL, DLBCL, primary mediastinal B-cell
lymphoma, MZL, and CLL. First, we found that all BLs were
Table 1. Support vector machine model applied to BLs and DLBCLs
to discriminate eBL and HIV-BL from DLBCL cases
Identifier Disease Confidence measure
BL_001_SI.CEL BL 0.9257281
BL_002_SI.CEL BL 0.71880513
BL_003_SI.CEL BL 0.7978547
BL_004_SI.CEL BL 0.8448915
BL_005_SI.CEL BL 0.8881669
BL_006_SI.CEL BL 0.95476633
BL_007_SI.CEL BL 0.73522216
BL_008_SI.CEL BL 0.78618616
BL_009_SI.CEL BL 0.796209
BL_010_SI.CEL BL 0.7188346
BL_011_SI.CEL BL 0.77551955
BL_012_SI.CEL BL 0.7787996
BL_013_SI.CEL BL 0.7188282
HIV-BL_001_BO.CEL HIV-BL 0.71878594
HIV-BL_002_BO.CEL HIV-BL 0.7652723
HIV-BL_GSM429903.CEL HIV-BL 0.7188018
HIV-BL_GSM429907.CEL HIV-BL 1
HIV-BL_GSM429910.CEL HIV-BL 0.8241211
HIV-BL_GSM429915.CEL HIV-BL 0.95909286
For all identifiers listed, the predicted disease was BL. The support vector
machine model used the molecular signature described by Staudt and Dave et al26
and had an accuracy of 100%.
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grouped within one cluster, presenting with relatively homoge-
neous profiles (Figure 1). Interestingly, we also found that the
GEPs of DLBCL originating in HIV patients were more inti-
mately related to those of BLs (and, specially, eBL and HIV-BL)
than to the other DLBCLs (Figure 1). Apparently, such intriguing
phenomenon was not related to the EBV status. In fact, almost all
HIV samples, both EBV and EBV, clustered apart, close to BLs
(Figure 1). However, HIV DLBCL cases showed a significant
enrichment in MYC targets compared with HIV cases.25 Thus, it
is conceivable that a MYC-dependent signature had a major effect
on the clustering, leading HIV DLBCLs close to BLs.
Second, we tested whether the recently described molecular
signature distinguishing sBL from DLBCL17,26 was able to discrimi-
nate eBL and HIV-BL from DLBCL as well. Indeed, by applying a
support vector machine algorithm for class prediction, 13 of 13 eBLs
and 6 of 6 HIV-BLs were correctly identified as BLs (overall
accuracy, 100%; Table 1).
Taken together, these results showed that BLs have a relatively
homogeneous molecular profile, different from those of other
B-NHLs, independently from the clinical setting.
BL subtypes present differences in their GEP
We then investigated whether BL subtypes can be differentiated
according to their GEP. To address this issue, we directly compared
the GEPs of eBL, sBL, and HIV-BL. First, Principal Component
Analysis (PCA) and unsupervised hierarchical clustering showed
that the 3 subtypes can be only roughly distinguished according to
Figure 2. BL subtypes present with differences in their GEPs. Both
unsupervised analyses, principal component analysis (A) and hierarchical
clustering (B), could discriminate the 3 different BL subtypes. Notably, eBL
and HIV-BL appeared to be strictly related.
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their GEPs. In particular, eBL and HIV-BL appeared to be strictly
related, with quite similar molecular features, whereas sBL was
relatively more distinct (Figure 2). Interestingly, HIV-BLs were
close to eBLs independently to the EBV status. In fact, they all
clustered with eBL (Figure 2), although 5 of 6 were EBV (see
supplemental Table 1 and Deffenbacher et al25).
Subsequently, we performed a supervised comparison of the
3 groups (Kruskal-Wallis and analysis of variance tests, Bonferroni
correction; P  .05). Two hundred twenty-two probe sets turned
out to be differentially expressed among BL subtypes (Figure 3A).
Interestingly, the genes differentially expressed among BL sub-
types were enriched in functional categories such as proliferation,
cell-cycle regulation, transcription, and nucleic acid metabolism
(Figure 3B). In addition, by looking for specific pathways, we
found B-cell receptor (BCR) signaling and tumor necrosis factor 
(TNF)/nuclear factor B (NF-B) to be significantly overrepre-
sented. More specifically, however, we found that eBL and HIV-BL
had almost identical GEPs, with only a minimal set of genes
Figure 3. BL subtypes present with differences in their GEPs. (A) Supervised approach identified 222 probe sets differentially expressed in eBL versus sBL versus HIV-BL
(Kruskal-Wallis test). (B) The corresponding genes belonged to relevant functional categories, including cell cycle regulation, nucleic acid metabolism, proliferation, and
transcription. (C) Supervised analysis of eBL versus sBL identified 129 genes differentially expressed.
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differentially expressed (Figure 3A). Although the molecular
signatures of eBL and sBL were overall similar, it was possible to
identify 155 probe sets, corresponding to 129 unique genes, differen-
tially expressed in the 2 groups with a fold change 2 (Figure 3C;
supplemental Table 1). Notably, when we divided eBL and sBL in
training and test sets (18 and 16 cases, respectively), we could
identify a set of genes (N  73) that to ones with maximal
differences in expression in the 2 groups; by building a Support
vector machines (SVM) model that was based on these 74 genes,
we could correctly classify all the samples belonging to the test set as
eBL or sBL (Table 2; supplemental Table 2). Similarly, these genes
turned out to be differentially expressed in HIV-BL compared with
sBL as well (not shown).
Interestingly, because it was recently proposed that 6 miRNAs
are differentially expressed in eBL than in sBL (hsa-miR-191,
hsa-miR-374a, hsa-miR-193a-5p, hsa-miR-10b, hsa-miR-216b, and
hsa-miR-499-3p; H. Stein, personal communication, May 2010),
we identified their putative targets by using the PicTar Web
Interface (http://pictar.mdc-berlin.de; supplemental Table 4). We
then tested their expression in our panel by Gene Set Enrichment
Analysis (GSEA); we found that the eBL signature was signifi-
cantly enriched in such molecules (P  .01). In addition, we found
10 of 18 supposed targets of miR-127 (supplemental Table 4) to be
overexpressed in eBL cases. Notably, miR-127 has been recently
shown to be altered in EBV BLs.27,28 Finally, by GSEA, we found
only the above-mentioned miRNA targets to be significantly
enriched in eBL compared with sBL, whereas none of the other
categories included in the Broad Institute cytogenetic, functional,
regulatory-motif, neighborhood, and Gene Ontology sets was
enriched.
The proliferation signature of endemic BL relies on either MYC
expression and other factors
Because we found that eBL and sBL differed for genes involved in
cell cycle control, we investigated whether RBL2 abnormalities
might contribute to the molecular profile of eBL cases. In fact, we
recently suggested the possible role of RBL2, a tumor suppressor
gene belonging to the retinoblastoma family and basically respon-
sible for cell cycle control, in eBL pathogenesis.23 To address this
issue, we first used a reverse engineering algorithm (ARACNe) to
identify genes whose mRNA expression is directly correlated with
RBL2 activity in a set of GEPs obtained from both normal B cells
and a subset of B cell–derived tumors.19,29 The ARACNe-predicted
RBL2 network included 655 genes (supplemental Table 5). We then
tested whether the genes differentially expressed in eBL compared
with GC B cells were enriched in RBL2-related genes, and we
found a significant overlap between the 2 signatures (P  .0001).
As control, we first repeated the experiment by using the MYC
network inferred with the use of the same ARACNe algorithm and
recently described by Basso et al.19 Indeed, as expected, the eBL
signature was enriched in molecules identified by ARACNe as
MYC network genes (P  .0001). Moreover, because both MYC
and RBL2 regulate proliferation, we tested whether the RBL2
network depleted of the genes possibly belonging to both networks
was still significantly represented in the eBL signature. Indeed, the
enrichment was still significant (P  .0003).
Subsequently, we tested whether eBL was enriched in RBL2
network genes in comparison to sBL. Indeed, GSEA showed a
significant enrichment of such molecules in eBLs (P  .0003).
Finally, to further test the specificity of our result, we also
checked a gene list representing a generic cyclin/cell cycle
regulation pathway (and including RB family genes),30 and we did
not find any significant enrichment in eBL signature (neither vs GC
cells nor vs sBL). Taken together, these results underline the role of
additional events in eBL pathogenesis, proposing RBL2 as tumor
suppressor in this contest.
BL is closely related to GC cells
GC cells are currently considered the normal counterpart of BL.
However, on the basis of patterns in the IGH@ genes14 and peculiar
EBV-related molecule expression, the WHO classification could
not univocally recognize eBL origin, and even post-GC derivation
has not been excluded.1 To better understand the relationship
between BL subtypes and normal B cells, we first applied an
unsupervised approach and found that all BL cases clustered within
one group, being clearly distinct from normal B cells (Figure 4A).
Subsequently, we analyzed BLs for the expression of genes that are
differentially expressed in purified tonsillar GC (centroblasts and
centrocytes) versus non-GC B cells (naive and memory), as defined
previously by supervised analysis.20,31,32 The analysis indicated that
the BL cases are significantly more related to GC B cells than to
memory and naive B cells (Figure 4B), independently from the
clinical subtype (ie, endemic vs sporadic vs HIV-related). Simi-
larly, by applying a support vector machine algorithm for class
Table 2. Support vector machine model applied to a test set of BLs (10 sBL and 6 eBL) correctly classified all the samples
Identifier BL type Predicted phenotype (eBL vs sBL) Confidence measure
BL_010_SI.CEL eBL eBL 0.10512279
BL_009_SI.CEL eBL eBL 0.27623063
BL_013_SI.CEL eBL eBL 0.32283565
BL_008_SI.CEL eBL eBL 0.7022334
BL_012_SI.CEL eBL eBL 0.06943361
BL_011_SI.CEL eBL eBL 0.0914568
BL_U133_2472_67260.cel sBL sBL 0.63513815
BL_U133_2537_67262.cel sBL sBL 0.7420162
BL_U133_2466_69771.cel sBL sBL 0.5546262
BL_U133_2536_67423.cel sBL sBL 0.9092932
BL_U133_2538_67263.cel sBL sBL 0.7482758
BL_U133_2461_69770.cel sBL sBL 0.554709
BL_U133_2524_67261.cel sBL sBL 0.668497
BL_U133_2522_67264.cel sBL sBL 0.66908705
BL_U133_2464_69968.cel sBL sBL 0.6160269
BL_U133_2521_68968.cel sBL sBL 0.6725733
The model was applied with the use of a core gene set (N  73) obtained by supervised analysis of a training set of BLs (11 sBL vs eBL).
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prediction that was based on the above-mentioned signature, all but
2 BL cases (1 eBL and 1 HIV-BL) appeared to be more related to
GC cells (supplemental Table 6). Finally, GSEA was applied to
assess whether eBL cases present with possible enrichment in
post-GC programs; however, no significant enrichment was re-
corded as far as memory cells, plasma cells, or post-GC NHL (CLL
and MZL) signatures are concerned. Taken together, our results
indicate that all the different BL subtypes present with a molecular
profile related to that of GC cells.
BLs differ from GC cells for the expression of molecules
involved in proliferation immune response and BCR signaling
To identify genes and cellular programs altered as a consequence of
malignant transformation, we performed a supervised comparison
of BLs and normal GC B cells. In particular, we identified 1956 probe
sets, corresponding to 1331 genes differentially expressed by the
2 groups (BL subtypes vs normal samples; Figure 5; supplemental
Table 7). Specifically, 811 turned out to be down-regulated and
Figure 4. Relatedness of the GEP of BL to normal
B-cell populations. Analysis of genes associated in
normal B cells to the GC transitions in BL. The genes that
are differentially expressed in naive, memory, and GC
B cells during the GC transit were identified by super-
vised analysis. The expression of the transition genes is
investigated in BL. All BL cases are more related to GC
B cells than to naive/memory cells, irrespectively of the
clinical subtype (A). A cell-type classification is used to
measure the relatedness of BLs to naive/memory (NM)
and germinal center (GC) B cells. The gray area marks
95% of confidence; the P value decreases with increasing
distance from the x-axis (B).
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520 up-regulated in BL, respectively. Interestingly, such molecules
corresponded to relevant biologic processes, according to gene
ontology categories,33 some of which turned out to be significantly
enriched in BL signature, such as cell proliferation, immune
response/class II major histocompatibility complex antigen, phos-
phatidylinositol 3-kinase activity, signal transduction, and others.
In addition, among others, in BL we recorded higher expression
levels of chemokines, transcription factors (including MYC, which
served as internal control), and molecules involved in drug
metabolism and interaction with microenvironment. However,
among down-regulated genes, we found cell cycle regulators,
surface molecules, chemokines and receptors, and genes involved
in NF-B pathway (for details, see supplemental Table 8).
To better understand the functional consequences of gene
deregulation in BL, we investigated whether certain pathways were
specifically affected. Importantly, the signature characterizing BL
presented with a significant enrichment in molecules participating
to BCR, TNF/NF-B, and NOTCH signaling, as well as intracel-
lular cascade secondary to interleukin stimulation.
When the analysis was performed by dividing BL cases into
training (N  20) and test (N  20) sets, analog results were
obtained, and a cell classifier easily recognized BLs as tumor
samples (supplemental Figure 2).
MYC overexpression and RBL2 silencing affect cell
proliferation
To validate the GEP findings, we aimed to assess the possible
contribution of RBL2 abnormalities in eBL pathogenesis by
functional in vitro and in vivo assays. First, we focused on the
effects of its silencing, which mimics RBL2 point mutations
occurring in eBL.15,22,23 Thus, we engineered EBV B cells to
either overexpress MYC or silence RBL2. The latter was obtained
with the use of 2 different short hairpin RNA directed against RBL2
(4 and 9), which induced equivalent silencing. Thus, for simplicity,
only results relative to clones expressing sh4 are presented. Stable
transfectants were then checked by immunofluorescence (supple-
mental Figure 3). Because these 2 genes affect cell proliferation,
the proliferation rate of our clones was checked by cell count,
whereas cell cycle was analyzed by fluorescence-activated cell
sorting analysis. As controls, cells stably expressing either MYC or
short hairpin RNAs against RBL2, as well as empty vector-
expressing cells, were used. As expected, both MYC overexpres-
sion and RBL2 silencing led to an increase of the proliferation rate,
their combination conferring the highest advantage (supplemental
Figure 4). Fluorescence-activated cell sorting analysis was then
performed to monitor cell cycle. Our results confirmed that MYC
overexpression and RBL2 silencing cooperate in accelerating cell
proliferation, because the G2/M cell population significantly in-
creased in double transfectants (supplementary Figure 5).23 Intrigu-
ingly, in the same cell population a reduction of the number of
apoptotic cells was observed, which is in line with the proapoptotic
role of RBL2/p130 (supplemental Figure 5).
Effects of MYC overexpression and RBL2 silencing on the
tumorigenic potential of LCL cells in vitro
The neoplastic properties of the LCL cells engineered to carry
either MYC overexpression or RBL2 silencing or both were then
assessed by testing their ability to form colonies in soft agar. In this
Figure 5. Identification of genes differentially expressed in BL and
normal GC B lymphocytes. Supervised analysis was performed with
the use of 40 BL samples versus the 10 normal GC B-cell samples
identified as the closest normal counterparts. The analysis identified 1956
probe sets (1331 genes) that are differentially expressed in BLs versus
normal samples (supplemental Table 6).
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anchorage-independent growth test, we found that the colony-
forming potential of double transfectants (pshRb2  pcDNA3-
MYC) was significantly higher than those of single transfectants
(pshRb2 and pcDNA3-MYC, respectively; P  .004) as well as of
mock-transfected cells (pcDNA3; P  .0001). In particular, the
number of colonies was increased 43%, 64%, and 107% after
pcDNA3-MYC, pshRb2, and pshRb2  pcDNA3-MYC transfec-
tion, respectively (Figure 6A)
Effects of MYC overexpression and RBL2 silencing on the
invasion capability of LCL cells in vitro
Because double transfectants showed higher tumorigenicity in vitro
compared with either single transfectants, to further investigate
their transforming potential we tested whether they had increased
capability to invade the extracellular matrix. We found that both
RBL2 silencing and MYC overexpression confer the cells with the
Figure 6. RBL2 silencing contributes to cell cycle deregu-
lation in vitro and in vivo. (A) Soft agar assay: Comparison
between the ability of empty vector–transfected cells and
pcDNA3-MYC, pshRb2, or double-transfected cells to growth
in soft agar. Error bars represent standard deviation between
triplicates. In double transfectants, we observed significantly
higher colony numbers than in single ones (P  .04).
(B) Matrigel invasion assay: Comparison between the ability
of empty vector–transfected cells and pcDNA3-MYC,
pshRb2, or double-transfected cells to cross the extracellular
matrix. Error bars represent standard deviation between
triplicates. In double transfectants, significantly higher migra-
tion was detected (P  .05). (C) In vivo test indicated higher
engraftment capability for double transfectants than for
single ones.
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capability to cross the extracellular matrix (Figure 6B). However,
in line with previous results, double transfectants turned out to be
more aggressive than single ones as far as matrix invasion was
concerned. In particular, cell migration was increased by 1.3-, 1.64-, and
2.1-fold after pcDNA3-MYC, pshRb2, and pshRb2 pcDNA3-MYC
transfection, respectively (P  .05; Figure 6B).
Intriguingly, we also observed that RBL2-silenced cells showed
a slightly higher ability of digesting extracellular matrix, which
may depend on the ability of RBL2/p130 to modulate the expres-
sion of proteins involved in cell adhesion (not shown).23
Effects of MYC overexpression and RBL2 silencing on the
tumorigenic potential of LCL cells in vivo
To test the capability of the 3 transfectants (pcDNA3-MYC,
pshRb2, and pshRb2  pcDNA3-MYC) of generating tumors in
vivo, we injected them into nude mice. Interestingly, tumor formation
was observed only in animals receiving pshRb2 pcDNA3-MYC
cells. In particular, a bone marrow B-cell lymphoma developed in
3 of 5 experiments (Figure 6C). However, other sites such as the
central nervous system, heart, spleen, liver, lymph nodes did not
present with tumoral infiltration. According to morphology and
phenotype, the tumor was classified as aggressive B-NHL because
criteria for a clear BL diagnosis were not fulfilled.
Immunohistochemical validation on tissue microarrays
As further validation of GEP, to investigate whether the up-
regulated mRNA levels of BL-associated genes corresponded to
elevated levels of the encoded proteins, we stained tissue microar-
rays containing 85 BL cases (including the cases subjected to gene
expression analysis) with the use of specific monoclonal and
polyclonal antibodies raised against the selected molecules. In
addition, we tried to assess whether the overexpression of these
molecules was really because of the neoplastic cells or was perhaps
secondary to reactive elements. In particular, we evaluated the
expression of CYR61 and SPARC, because of their potential
biologic relevance. We found CYR61 expressed in all BL cases
(Table 3). Specifically, a positive staining was observed in neoplas-
tic elements at both the cytoplasmic and nuclear levels. However,
in normal lymphoid tissues, CYR61 was weakly expressed by
scattered GC cells and by occasional mantle cells (Figure 7). In
addition, we tested a panel of B-NHL (CLL, hairy cell leukemia,
FL, and DLBCL) and found a proportion of cases to be CYR61
within each entity (Table 3). However, a high degree of variability
was observed in most instances. Furthermore, we studied SPARC
and found it to be expressed in all BLs (Table 3). Indeed, intense
cytoplasmic positivity was detected in virtually all neoplastic
elements. Conversely, in reactive lymphoid tissues, SPARC expres-
sion was mainly confined to GCs where it stained macrophages and
follicular dendritic cells and scattered lymphoid elements (Figure
7). Concerning other B-NHLs, a variable proportion of cases
(slightly higher in GC-derived neoplasms) presented SPARC
expression in tumor cells (Table 3).
Discussion
Here, we studied for the first time the GEPs of all BL subtypes and
compared them with those of a large panel of B cell–derived
malignancies and normal B lymphocytes. First, we showed that BL
is a distinct entity, supporting the current WHO classification.1 In
fact, we showed that the GEP of all BL subtypes is quite
homogeneous and distinct from those of other lymphomas. In
addition, importantly, we showed that the recently described BL
molecular signature can effectively distinguish not only sBL but
also eBL and HIV-BL from DLBCL.
However, it has been questioned whether the different BL
subtypes, being characterized by peculiar epidemiologic and
clinical features, may as well differ in cellular biology and
pathogenetic mechanism. Interestingly, we found that eBL and
HIV-BL had almost identical GEPs, whereas sBL cases were
relatively more different. Of note, differences between eBL and
sBL regarding significant pathways such as BCR, TNF/NF-B,
and interleukin-dependent intracellular cascades, possibly reflect
the different clinical contests. In fact, because eBL is known to
have an onset in a contest of chronic antigen stimulation (in primis
EBV, malaria, and arbovirus infections),5 it was not surprising that
its molecular signature included many genes involved in immune
response regulation. Similar considerations can be then applied to
HIV-BL. However, whether the specific effects of EBV rather than
the ongoing antigenic stimulation (or a polyclonal stimulation by
superantigens) can be more relevant remain to be assessed.
Intriguingly, among the genes differentially expressed in eBL and
sBL (ie, bona fide, EBV and EBV cases), we found 10 of 18 of
the supposed targets of miR-127, the deregulation of which is a
consequence of EBV integration,27,28 supporting the causative role
of EBV in eBL development.5,15 However, it is notable that
HIV-BL, which were collected in western countries, did behave as
eBLs. In fact, not only are they known to be more similar to sBL at
the genomic level, in terms of MYC/IGH@ breakpoint,16 but they
were also mostly EBV. Thus, it is conceivable that other factors
(ie, chronic stimulation) might play a major role.
Interestingly, a significant difference between eBL and sBL also
consisted in the enrichment in genes belonging to the RBL2
network, which we defined in a large panel of normal and
neoplastic samples, with the use of a novel, quite effective
bioinformatic tool for reverse engineering (ARACNe).19,29,34 Nota-
bly, RBL2 is mutated and not efficient in eBL,22,23 and, as further
functional validation, we provided evidence that RBL2 silencing
can cooperate with MYC overexpression in altering cell cycle
control and invasion capability of EBV-infected cells. Thus,
although MYC ectopic expression is sufficient for tumor initia-
tion,35 the present data provided strong evidence of a consistent
role for additional events in eBL full establishment and progression.
Furthermore, we showed that all BL subtypes are definitely
related to GC B lymphocytes. In this regard, note that although sBL
is currently regarded as a GC-derived tumor, the cellular origin of
eBL has been largely questioned,1,14,15 and the histogenesis of eBL
has not been defined in the present WHO classification.1 In
Table 3. Immunohistochemical analysis on tissue microarrays
Sample SPARC CYR61
Chronic lymphocytic leukemia/SLL 20/59 14/24*
Follicular lymphoma 44/103 10/32†
Diffuse large B-cell lymphoma 49/72 11/17
Hairy cell leukemia 9/27 13/16
Burkitt lymphoma 85/85 85/85
Normal spleen 0/5‡ 0/5‡
Reactive lymph node 0/5‡ 0/5‡
Data are reported as n/N.
SLL indicates small lymphocytic lymphoma.
*Weak positivity ( 30% positive cells with weak staining, in presence of internal
control for proper reactivity).
†Partial positivity in all instances (10%-30% of positive cells).
‡Occasional B cell–positive.
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particular, on the basis of EBV-related molecule expression and SH
pattern, it has been suggested that eBL may derive from post-GC,
memory B cells.1,14,15 Our data clearly showed that all BL molecu-
lar profiles were closer to those of GC lymphocytes than to those of
memory cells. In addition, GSEA did not show any evidence of
possible enrichment in either memory or plasma cell programs in
eBL cells, whereas CD40 signaling appeared to be shut off (not
shown), consistently with an early GC biology.19 In all, on the basis
of morphology (medium-sized small centroblast-like cells),1 pheno-
type,1 genetics (ie, SH pattern and activation-induced cytidine
deaminase–dependent MYC translocation occurrence),14,36,37 and
global GEP, BL appears to correspond to an early GC cell.
Figure 7. Immunohistochemical analysis on tissue microarrays. Cases were considered as positive when 30% cells were stained (Olympus BX41 microscope equipped
with an Olympus UPlanFI 
 40/075 or 20/050 numerical aperture objectives and Olympus CAMEDIA C-7070 camera; Olympus Italia Srl; magnification
400; colors balanced
after acquisition with Adobe Photoshop). BLs mainly consisted of neoplastic elements with typical morphology in the majority of cases (GIEMSA; GM). SPARC and CYR61
stainings are shown in BL and reactive lymph nodes (LNs). In both instances, nonneoplastic B cells were mostly negative, with scattered CYR61 positivities in GC and mantle
(M) zones.
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However, it cannot be ruled out that EBV tumors may derive from
a later developmental stage, the differentiation arrest being because
of miRNA deregulation induced by EBV itself.27,28
Subsequently, we defined a consistent set of genes differentially
expressed in BL and normal GC cells, as a consequence of
malignant transformation. Importantly, we found that relevant
functional programs turned out to be altered, including those
related to immune response, cell cycle regulation, and BCR
signaling. As the latter is concerned, specifically, part of such
differences may reflect either the differentiation arrest of BL
neoplastic elements (ie, CB is substantially independent from BCR
signaling),38 as well as be the consequence of the neoplastic
transformation.
Finally, as further validation of gene expression data, immuno-
histochemistry was used to evaluate the expression of proteins
corresponding to genes overexpressed in BL versus normal GC
cells and according to potential biologic interest. Notably, both the
tested molecules, CYR61 and SPARC, turned out to be strongly
expressed by the neoplastic cells. This is of interest as such
molecules may have a significant role in BL pathobiology. In fact,
on the one hand, CYR61 expression has been related to malignant
transformation in different settings, including human lymphomas,
being also related to aggressive clinical behavior and drug resis-
tance.20,39,40 On the other hand, SPARC contributes to the acquisi-
tion of migratory and invasive properties that are recapitulated by
malignant tumor cells.41,42 In fact, evidence from SPARC-null in
vitro and in vivo settings suggest that SPARC is able to directly
affect NOTCH receptor signaling, thus determining the ability of
cells to respond to key environmental signals involved in cell fate
regulation, converging to the as–mitogen-activated protein kinase
pathway, which we found up-regulated in eBL despite a biased
BCR signal initiation.43,44 Thus, the up-regulation of SPARC
expression we observed in BL is in line with a cellular program
oriented toward proliferation, migration, and extracellular matrix
invasion, and that is poorly reliant on extracellular signals (also
supported by major histocompatibility complex protein down-
regulation). In BL, SPARC hyperexpression may represent a
molecular hub linking together many of the cellular programs we
found altered in BL, thus representing an appealing target for
focused studies.45 Interestingly, in this setting, SPARC up-
regulation might be sustained by MYC-driven miR-29–impaired
expression.46 Importantly, normal GC cells mostly lacked SPARC/
CYR61 expression; conversely, a proportion of B-NHL showed
expression of the 2, highlighting their possible role in tumor
development.
In conclusion, our study provided substantial insights on the
pathobiology of eBL, by offering novel evidence that may be
relevant for its classification and possibly future treatment. In fact,
we clearly showed that all BL subtypes have a homogeneous GEP.
In addition, we provided evidence that the molecular profile of BL
subtypes is slightly, although significantly, different, suggesting
different pathogenetic mechanisms and the role of infectious
agents. Because the terms sporadic and endemic are exclusively
based on epidemiologic basis, a better classification should take
into account the causative pathogenetic mechanisms.
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